Kornimate/medical-research-clean huggingface dataset:
metabolic syndrome in psoriasis and psoriatic arthritis and correlation with serum omentin and visfatin levels

Conditions: Psoriasis Vulgaris; Psoriatic Arthritis; Metabolic Syndrome

Summary: in this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. at the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by pasi psoriasis, clinical activity score for psoriatic arthritis). the patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. for the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. aha / nhlbi, 2005 (revised atp iii criteria) criterion for the diagnosis of metabolic syndrome will be used. omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.


Eligibility criteria:
inclusion criteria: 1. patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic 2. patients older than 18 years 3. patients who accept dermatological and rheumatic examination 4. patients not receiving systemic treatment related to the disease in the last 1 month exclusion criteria: 1. patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis 2. patients under 18 years 3. patients who do not accept dermatological and rheumatic examination patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Keywords: psoriasis vulgaris psoriatic arthritis metabolic syndrome omentin visfatin
assessment of delayed-type hypersensitivity reactions to sars-cov-2 peptide antigens

Conditions: Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Summary: this dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedtnx-2100, synthesized sars-cov-2 peptide antigens and assess the presence and magnitude of dth reactions.

three ips (tnx-2110, tnx- 2120, tnx-2130) will be administered by intradermal injection (0.1 ml) in two concentration strengths (stage 1: "1:10 dilution" and stage 2: "undiluted"). subjects will also receive one intradermal injection (0.1 ml) of a positive control (candin®), and one intradermal injection (0.1 ml) of a negative control "diluent".

Eligibility criteria:
inclusion criteria: male or female subjects aged 18 - 65 years of age, inclusive, in good general health as determined by medical evaluation subject receives a negativesars-cov-2 pcr test result at their screening or baseline visit exclusion criteria: subjects will be excluded if they have clinically significant underlying conditions associated with high risk for severe covid-19 infections as identified by the centers for disease control and prevention (cdc) (appendix 2). these conditions include, but are not limited to: chronic obstructive pulmonary disease, diabetes mellitus (type 1 and 2), obesity, hypertension, heart disease, and cerebrovascular disease.
inhaled budesonide for altitude illness prevention

Conditions: Altitude Sickness

Summary: a randomized, double-blinded study administering budesonide, a medication to reduce inflammation in the lungs, to healthy volunteers to examine effects on altitude illness prevention by spending 18 hours overnight at 14,000 ft elevation.

a randomized, double-blinded study will be conducted to validate the results of previous literature on the use of budesonide in the prevention of altitude sickness. it will be conducted using healthy participants overseen by experienced wilderness medicine and altitude researchers from the altitude research center at university of colorado denver. participants will be recruited from the denver community and prescreened for eligibility via phone. 100 participants, after consenting, will have baseline data and blood collected and will begin budesonide therapy 72 hours prior to being taken from denver to pikes peak, where they will be observed at altitude for 18 hours. patients will have the opportunity to withdraw consent at any time and will be monitored continuously by physician-researchers. data collection and blood draws will be performed at specific time points and analyzed for efficacy of budesonide vs. placebo in the incidence of altitude sickness.

Eligibility criteria:
inclusion criteria: * healthy, altitude naive, 21-40 years old exclusion criteria: * smokers * pregnancy * hx of asthma * current inhaled steroid use * those with diseases or disorders known to be affected by hypoxia or the drugs used in this study such as * migraine or other chronic headaches, * sickle cell trait or disease, or * diabetes * history of significant head injury or seizures * taking any medication (over-the-counter or prescription) or herbal supplements * a known hypersensitivity reaction to budesonide * inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day * exposure to high altitude above 2000m in the previous 1 month or * those who have been on an airline flight over six hours (airplane cabins are pressurized to an elevation that can approximate exposure to high altitude)
impact of differential and systematic diagnosis of dengue, chikungunya and malaria on patient management and antibiotic use in west africa

Conditions: Dengue; Chikungunya; Malaria

Summary: the differential and systematic diagnosis of malaria, dengue and chikungunya in patients with fever (≥38.5°c) of undetermined etiology would allow the identification of infection by these pathogens and thus limit the inappropriate use of antibiotics (discontinuation or non-initiation) and optimize the clinical management and prognosis of patients.

the research hypotheses are as follows: * systematic diagnosis of malaria, dengue and chikungunya using diagnostic tests would improve the clinical management of patients with fever of undetermined etiology and reduce the misuse of antibiotics (discontinuation or non-initiation) and associated resistance. * improved management is associated with a reduction in the use of hospital resources, professional inactivity and an improvement in the quality of life and satisfaction of patients.

Eligibility criteria:
inclusion criteria: * subjects aged ≥ 18 years * patient with fever (≥38.5°c) and at least two of the following symptoms in the last 10 days: * severe headache * retro-orbital pain * muscle and joint pain * nausea * vomiting * adenopathy * rash * abdominal pain * asthenia * spontaneous bleeding (purpura, epistaxis, haematemesis, etc) * willingness and ability to provide two 4 ml blood samples * willingness to provide one drop of blood per capillary sample * informed and signed consent exclusion criteria: * subjects aged \< 18 years * pregnant women * breastfeeding women * patient's refusal to participate in the study

Keywords: diagnosis clinical management antibiotic patient management immunoassays arboviruses west africa antibiotic resistance dengue malaria chikungunya
study of oral rxdx-101 in adult patients with locally advanced or metastatic cancer targeting ntrk1, ntrk2, ntrk3, ros1, or alk molecular alterations.

Conditions: Locally Advanced Solid Tumors; Metastatic Solid Tumors

Summary: entrectinib (rxdx-101) is an orally available inhibitor of the tyrosine kinases trka (coded by the gene ntrk1), trkb (coded by the gene ntrk2), trkc (coded by the gene ntrk3), ros1 (coded by the gene ros1), and alk (coded by the gene alk). molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (nsclc), colorectal cancer (crc), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment. phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended phase 2 dose. safety and efficacy will be assessed in the dose expansion portion of the study.


Eligibility criteria:
key inclusion criteria: * histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ntrk1, ntrk2, ntrk3, ros1, or alk molecular alteration. * measurable disease according to recist version 1.1. * prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs. * prior radiotherapy is allowed * patients with controlled asymptomatic central nervous system involvement are allowed. * resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03 grade less than or equal to 1. * eastern cooperative oncology group (ecog) performance status (ps) ≤ 2. * adult patients age 18 years or older. * life expectancy of at least 3 months. key exclusion criteria: * current participation in another therapeutic clinical trial. * prior treatment with entrectinib. * history of prolonged qtc interval (e.g., repeated demonstration of a qtc interval \> 450 milliseconds). * history of additional risk factors for torsade de pointes (e.g., family history of long qt syndrome). * known active infections (bacterial, fungal, viral including hiv positivity). * gastrointestinal disease (e.g., crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption. * known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis. * peripheral neuropathy ≥ grade 2.
confocal laser endomicroscopy (cle) in patients with diarrhea

Conditions: Diarrhea

Summary: the main objective of this study is to determine the frequency of different gastrointestinal disorders as the cause of diarrhea in patients at a tertiary referral center using confocal laser endomicroscopy.

background: diarrhea is characterized by frequent, loose, and watery bowel movements. common causes include various gastrointestinal infections (e.g. clostridium difficile, salmonella), inflammatory bowel disease (ulcerative colitis, crohn´s disease), drugs (e.g. antibiotics) and malabsorption syndromes (e.g. celiac and whipple's disease). confocal laser endomicroscopy (cle) is rapidly emerging as a valuable tool for gastrointestinal endoscopic imaging, enabling the endoscopist to obtain an "optical biopsy" of the gastrointestinal mucosa during the endoscopic procedure. scope: in patients with diarrhea. methods: patients were randomized in two groups. group 1: patients underwent standard video colonoscopy for the evaluation of their symptoms. group 2: during the endoscopic procedure cle will be performed additionally. procedure: the patient underwent colonoscopy. in group 2 patients´ will receive intravenous fluorescein or topical mucosal staining with acriflavin or cresyl violet during the procedure, followed by in-vivo cle of the tissue. confocal images are digitally saved and analyzed afterwards.

Eligibility criteria:
inclusion criteria: * written informed consent * age 18-85 years * ability of subjects to understand character and individual consequences of clinical trial * subjects undergoing colonoscopy exclusion criteria: * inability to provide written informed consent * severe coagulopathy (prothrombin time \ 50 s) * impaired renal function (creatinine \> 1.2 mg/dl) * pregnancy or breast feeding * active gastrointestinal bleeding * known allergy to fluorescein, acriflavin or cresyl violet * residing in institutions (e.g. prison)

Keywords: patients with diarrhea
treatment of keloids with fractional erbium laser-assisted 5-fluorouracil versus laser-assisted corticosteroid

Conditions: Keloid Scar

Summary: this is a split-scar study with a target sample size of 20. there are two interventions: fractional erbium:yag-assisted drug delivery of 5-fluorouracil and fractional erbium:yag-assisted drug delivery of triamcinolone acetonide. patients will undergo treatments in a series of 4 treatments at approximately 4 week ± 1 week intervals. investigators will monitor for safety and continued benefit after the end of the interventional treatment.


Eligibility criteria:
inclusion criteria 1. age 18-89 2. has one large keloid scar or at least two similar but separate keloid scars 3. keloid present for at least 1 year exclusion criteria 1. currently pregnant 2. currently breastfeeding 3. have taken oral retinoids within 6 months of study initiation 4. has had keloid treatment within 1 month of study initiation 5. has active infection at treatment site 6. has active malignancy 7. presence of pedunculated keloid(s) or keloid(s) that are judged to be best treated with surgical excision first 8. hypertrophic scars 9. known hypersensitivity to tac or 5-fu 10. chronic systemic corticosteroid or immunosuppressive medication use 11. has intolerance to anesthesia 12. has known connective tissue disease 13. has known infectious disease
safety and effectiveness of the device "nit-occlud® pda-r"

Conditions: Congenital Heart Disease

Summary: the purpose of this study is to evaluate the safety and the effectiveness of the device "nit-occlud® pda-r" in the percutaneous closure of patent ductus.

during the years 2003 to 2008, the cardiological medical center "kardiozentrum" evaluated 1136 patients with echocardiographic studies, 14.7% of the patients were diagnosed with patent arterial duct. the pda is an abnormal communication between the aorta and pulmonary artery. untreated it can rise the intrapulmonary pressure and lead to serious complications like cardiac insufficiency. the incidence of ducts as an isolated heart disease is between 3.6 and 7% of all congenital heart diseases at sea level, and 10 - 14% at high altitude; rising up to 20% in cities at more than 2.500 m about sea level. the ducts at high altitude are generally wider and larger than at sea level. one treatment alternative is a percutaneous transluminal implantation of a permanent implant which closes the defect. the device under investigation "nit-occlud® pda-r" is developed for closure of the pda with a minimal diameter of 2-8 mm. the device performs the function of generating the defect occlusion by the body itself. the implant stimulates the body to generate an epithelium over the implant so that the pda closes.

Eligibility criteria:
inclusion criteria: * clinical and echocardiographic compatibility with pda without associated heart disease requiring surgical solution * minimum diameter of the pda 2 to 8 mm * systolic pulmonary pressure measured during cardiac catheterization, not on pass 2/3 of the values of the systolic systemic pressure * weight higher than 10 kg, regardless of age * patients who were diagnosed and recruited during the period 2009 - 2010 * patients with trisomy 21 also fulfill the previous criteria, the number of patients with t21 will not exceed 10% of the entire group of patients. * letter of consent signed by parents or legal guardian relative exclusion criteria: * infections that occur during acute bacteremia, viremia, which can be treated * febrile syndrome * tooth decay * once the acute solved considering the patient's inclusion into the study exclusion criteria: * pregnant women * pulmonary hypertension, increased to 2 / 3 of systemic pressure * eisenmenger syndrome * other associated heart disease, requiring surgical solution * immuno-compromised patients * pathology oncology * hematologic or coagulation disorders * allergy to contrast medium * atypical or calcified ductus * parents or legal guardians who do not accept the risks of catheterization * parents or legal guardians and patients who do not accept to sign the letter of consent or who revoke the consent. * patients who participated in another clinical investigation during the last 3 months

Keywords: ductus patent ductus arterious "nit-occlud® pda-r" interventional closure of pda percutaneous closure
minimization of intralipid versus omegaven

Conditions: Cholestasis; Parenteral Nutrition Associated Liver Disease (PNALD)

Summary: prolonged use of parenteral nutrition can lead to parenteral nutrition associated liver disease (pnald). the purpose of this study is to determine the effect of treatment with a smaller amount lipid minimization) of our standard soybean oil based intravenous lipid emulsion (intralipid) versus a fish-oil based lipid emulsion (omegaven) in infants with severe cholestasis.

infants meeting eligibility will be randomized to receive either 1g/kg/day of intralipid® 20% or 1g/kg/day omegaven® 10%. infants randomized to intralipid® whose conjugated bilirubin level rises \>100umol/l will be crossed over to receive 1g/kg/day omegaven®. monitoring includes liver function tests (ast, alt,alp, ggt, conjugated bilirubin), fatty acid profile (rbc and serum fatty acids; triene/tetraene ratio), inr (coagulation profile) and cytokine measure (inflammatory markers).

Eligibility criteria:
inclusion criteria: * infants admitted to neonatal intensive care unit * severe cholestasis, defined as conjugated bilirubin greater than 35 * receiving at least 60% calories by iv infusion and expected to require intravenous nutrition for at least an additional 28 days * signed consent exclusion criteria: * hepatitis (torch or other viral infection) * primary liver disease as etiology of cholestasis * clinically severe bleeding not able to be managed with routine measures * lethal congenital abnormalities * congenital heart disease associated with right heart dysfunction
comparison between ondansetron 8 mg and lidocain 40 mg in preventing pain due to propofol injection

Conditions: General Anesthesia With Propofol

Summary: this study aims to compare the effectivity between ondansetron 8 mg and lidocain 40 mg in preventing pain due to propofol injection

approval from ethical committee of faculty of medicine universitas indonesia was acquired prior conducting the study. subjects were given informed consent before enrolling the study. non-invasive blood pressure (nibp) monitor, ecg and pulse-oximeter was set on the subjects in the operation room. after a tourniquet made from nibp cuff were inflated, subjects were given either ondansetron 8 mg or lidocain 20 mg intravenously, then the tourniquet was set off. hemodynamic data was recorded. propofol 1 mg/kg of body weight (bw) injection was given. verbal rating scale was used to measure pain at 0 s, 5 s and 30 s. data was analyzed using statistical package for the social sciences (spss), for numeric data using uni-variate analysis and bi-variate analysis. significant value is p\<0.05.

Eligibility criteria:
inclusion criteria: * subjects aged 18-65 years old * subjects were planned to undergo general anesthesia with propofol * subjects with body mass index (bmi) 18-35 kg/m2 * subjects with american society of anesthesiologists (asa) physical status of i-ii * subjects with signed informed consent. exclusion criteria: * subjects with allergies to propofol, lidocain, ondansetron * subjects with massive cardiac disorder * subjects with cardiac rhythm disorder with or without treatment * subjects with unstable hemodynamic * subjects with contraindication to propofol, lidocain, ondansetron * subjects with intubation and ventilation difficulty * subjects with decreased consciousness, seizure history or head injury * subjects with analgesic treatment history * subjects with pregnancy. drop out criteria: * subjects with allergic reactions induced by propofol, lidocain, ondansetron * uncooperative subjects * subjects in emergency * subjects with difficult vein access in the dorsum manus * subjects with infection and/or inflammation in the planned intravenous cannulation location.

Keywords: lidocain ondansetron pain propofol
database of pelvic inflammatory disease

Conditions: Inflammatory Pelvic Disease

Summary: the aim of this prospective study is to collect data on in-patients with pelvic inflammatory disease(pid) at kangbuk samsung hospital.

the aim of this prospective study is to collect data on in-patients with pelvic inflammatory disease(pid) at kangbuk samsung hospital. if patients agree to participate in this clinical trial, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. the research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.

Eligibility criteria:
inclusion criteria: * all in-patient with pid who diagnosed at kangbuk samsung hospital exclusion criteria: * secondary pid caused by other surgical problem or disease * an inability to fill-up the informed consent
platelet reactivity, b-amyloid, mots-c and mortality of type ii diabetics with cad

Conditions: Diabetes; Clopidogrel Resistance; Amyloid; Insulin Resistance

Summary: increased circulating b-amyloid and decreased mitochondrial-derived peptide (mots-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. the investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with coronary artery disease

in type ii diabetic patients with coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (adp) by light transmission aggregometry (ltamax), as a marker of on-clopidogrel treatment platelet reactivity ii. malondialdehyde (mda), as oxidative stress marker, mitochondrial-derived peptide mots-c and b-amyloid. blood levels.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients with coronary artery disease, documented by coronary angiography, * both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (dapt), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study exclusion criteria: * abnormal renal function (creatinine\> 2.5 mg / dl), * hepatic failure (bilirubin\> 2 mg / dl), * active malignancy, * patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd, * patients with a history of hemorrhagic mood, * patients with thrombocytopenia (plts \< 100x109 / l) and * anemia (hct \<28%).